However, further large studies are required to confirm the role of CETP, SREBF-2, PEMT, IFNL4, and PPARGC1A gene polymorphisms in the susceptibility and pathogenesis of NAFLD in lean or non-obese individuals. This evidence concerns the gene PPARGC1A and metabolic dysfunction-associated steatotic liver disease.